T3 Pharmaceuticals AG news
T3 Pharmaceuticals AG – a biotech company focused on immuno-oncology – wins the SEF award 2021 in the category High-tech/Biotech.
In a multi-step selection process and among 107 applicants the distinguished jury has bestowed T3 Pharma with the SEF award 2021. «We are honored to receive such a prestigious price from the Swiss Economic Forum», commented Simon Ittig, CEO of T3 Pharma. «We would like to thank the jury for
T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech advancing immuno-oncology with its bacteria-based protein delivery platform, today announced the closing of its third financing round, raising over 25M CHF.
The financing was co-led by existing investors, including the Boehringer Ingelheim Venture Fund (BIVF), Reference Capital SA, Wille Finance AG and private investors, who all participated in the round. This latest financing brings T3 Pharma’s to
T3 Pharmaceuticals AG (T3), a Basel (Switzerland)-based company focusing on immuno-oncology, closes its second financing round of over 12M CHF with existing investors joined by «Boehringer Ingelheim Venture Fund» (BIVF) and «Reference Capital SA». To progress into the clinical phase, T3 appoints Claire Barton as Chief Medical Officer, strengthens its development team and announces the clinical advisory board.
«We are very pleased to be jo
T3 Pharmaceuticals AG – a biotech company in Basel focused on immunooncology – wins the W.A. de Vigier Foundation’s highest endowed award for startup companies in Switzerland with CHF 100,000 in prize money.
«We are honored to receive the W.A. de Vigier Foundation’s oldest and highest endowed sponsorship award and would like to thank the foundation and foundation board for recognizing the potential of our immuno-oncology approach. Our tha
T3 Pharmaceuticals (“T3 Pharma”), a biotech company with a focus on immuno-oncology, today announced it has been named “2018 Science Start-Up of the Year” by Falling Walls Venture. The award honors emerging scientist-entrepreneurs for their breakthrough business models.
The Falling Walls Conference in Berlin, Germany, annually invites the world’s leading scientists to identify trends, opportunities and solutions for global challe
T3 Pharmaceuticals Ltd (“T3 Pharma”), a Swiss-based biotechnology company specializing in breakthrough bacteria-based cancer therapies, today announced its selection for the second stage of BaseLaunch’s accelerator program. T3 Pharma is one of six companies that qualified for this next phase. In addition to industry access and expert knowledge, T3 Pharma receives a non-dilutive funding to support its scientific research until the next value inflection milestone.
The Gebert Rüf Stiftung has announced the winners of the call 2016 «Microbials – Direct Use of Micro-Organisms». Amongst the supported projects is T3 Pharma’s innovative bacteria-based cancer therapy. The applied research project takes place at the University of Basel, the results will allow T3 Pharma to expand its activities in the field of cancer treatment using live bacteria.
With the call «Microbials – Direct Use of Micro-O
T3 Pharmaceuticals Ltd (“T3 Pharma”), a Swiss-based biotechnology company specializing in breakthrough bacteria–based cancer therapies, today announced the successful closing of its first financing round. The funding has been provided by private Swiss investors and will secure further growth of the company, in particular the expansion of research activities and the initiation of preclinical development.
The financing round compleme
T3 Pharma has been awarded the CTI Start-up Label by the Commission for Technology and Innovation CTI.
The label is the result of a coaching process that allowed T3 Pharma to refine its corporate strategy. T3 Pharma is honored to have received the Start-up Label which is "a seal of quality, a certificate of achievement, and a sign of credibility and readiness for sustainable growth".